pursuant

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Basel, August 7, 2025 – Sandoz…

1 week ago

LINE Investors Have Opportunity to Lead Lineage, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--$LINE--The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit…

2 weeks ago

HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock

July 18, 2025 16:05 ET  | Source: HOOKIPA Pharma Inc. NEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) --…

4 weeks ago

Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessas Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist

July 04, 2025 03:00 ET  | Source: Nxera Pharma Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma…

1 month ago

BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate

July 02, 2025 01:00 ET  | Source: BioVersys Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, July 02,…

1 month ago

OSE Immunotherapeutics met jour linformation sur les procdures en cours

OSE Immunotherapeutics provides an update on ongoing proceedings NANTES, France, July 2, 2025, 8 AM – OSE Immunotherapeutics SA (ISIN:…

1 month ago

WhiteHawk Completes Tender Offer for Acquisition of PHX

PHILADELPHIA--(BUSINESS WIRE)--WhiteHawk Income Corporation (together with WhiteHawk Energy, LLC and their respective subsidiaries, “WhiteHawk” or the “Company”) announced that a…

2 months ago

Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update

June 19, 2025 01:00 ET  | Source: Addex Therapeutics Strong cash position of CHF2.8 million at end of Q1 2025GABAB…

2 months ago

FOBI AI Inc. Announces Closing of the Sale of German Subsidiary

June 12, 2025 16:53 ET  | Source: Fobi AI Inc. Vancouver, BC, June 12, 2025 (GLOBE NEWSWIRE) -- FOBI AI…

2 months ago

Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant…

2 months ago